Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01916928 · ClinicalTrials.gov registry record
The Use of Cell Free Fetal DNA in the Maternal Blood in the Evaluation of Intrauterine Fetal Demise and Miscarriage
A clinical trial, sponsored by Medstar Health Research Institute.
- Completed
- Registry status
- 50
- Enrollment target
NCT01916928 is a clinical trial that has completed, run by Medstar Health Research Institute. The registered enrollment target is 50 participants.
The verdict
NCT01916928 has completed, sponsored by Medstar Health Research Institute.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
Women presenting to Washington Hospital Center with fetal loss would be offered participation in the study. The objective is to determine if ccffDNA obtained from maternal blood is present in the setting of missed abortion or fetal demise. The investigators primary hypothesis is that cell free fetal DNA will be present in maternal blood in the presence of a failed pregnancy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01916928
The ClinicalTrials.gov registry entry for NCT01916928 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medstar Health Research Institute, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01916928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01916928 about?
NCT01916928 is a clinical study titled "The Use of Cell Free Fetal DNA in the Maternal Blood in the Evaluation of Intrauterine Fetal Demise and Miscarriage". Women presenting to Washington Hospital Center with fetal loss would be offered participation in the study. The objective is to determine if ccffDNA obtained from maternal blood is present in the setting of missed abortion or fetal demise. The investigators primary hypothesis is that cell free feta...
What is the current status of trial NCT01916928?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2013-05. Estimated completion is 2014-12.
Who is sponsoring clinical trial NCT01916928?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.